Company and Industry Summary Company: 药康生物 (Yaokang Biotechnology) Key Financial Performance - FY 2025 revenue reached 793 million yuan, representing a year-over-year increase of 15.5% [1] - Net profit attributable to shareholders was 144 million yuan, up 31.5% [1] - Non-recurring net profit stood at 118 million yuan, reflecting a significant increase of 55.8% [1] - Q4 2025 revenue was 218 million yuan, showing a growth of 22.9% [1] - Net profit for Q4 was 35 million yuan, a remarkable increase of 197% [1] - Non-recurring net profit for Q4 was 25 million yuan [1] Growth Drivers - Sales of mouse models experienced double-digit growth [1] - Functional efficacy CRO (Contract Research Organization) services grew at a rate of 30-40% [1] Industry Trends - The domestic industry is seeing an improvement in demand, with a recovery in the industrial sector [1] - Anticipated continued positive trends in the domestic market for Q1 2026 [1] - Overseas growth is projected at 40-50%, with an expanding network across Europe, America, and Asia [1] - High growth in overseas markets is expected to persist into 2026 [1] Long-term Outlook - Short-term optimism for the clinical pre-CRO sector in 2026 [1] - Long-term confidence in the business model of globally leading gene-edited mice, driven by China's engineering talent advantage [1] Industry Recommendations - Recommended stocks include 百奥赛图 (Baiaosaitu), 药康生物 (Yaokang Biotechnology), and 南模生物 (Nanmo Biotechnology) [2]

Core Insights - The article highlights the significant role of Shanghai Pudong Development Bank (SPDB) in promoting technology finance in the Yangtze River Delta region, particularly in cities like Nanjing and Hangzhou, since the establishment of the Sci-Tech Innovation Board six years ago [1][10] - SPDB has successfully supported over 240,000 technology enterprises and accounted for more than 70% of the companies listed on the Sci-Tech Innovation Board, with technology finance loans exceeding 100 billion yuan [1][9] Group 1: Technology Finance Development - SPDB is expanding its technology finance services by adopting a "technology finance + industry characteristics" approach, focusing on high-end manufacturing and high-tech enterprises [1][2] - The bank has established a comprehensive financial irrigation network for chain-leading enterprises through project loans, merger loans, and supply chain finance [2][3] - SPDB's supply chain finance solutions have alleviated financial pressures for upstream and downstream enterprises, enhancing cash flow and operational efficiency [3][5] Group 2: Case Studies of SPDB's Support - Nanjing Estun Automation Co., Ltd. is a representative case where SPDB provided tailored financial solutions to support its extensive supply chain, which includes over 1,000 customers and 800 suppliers [2][3] - Zhejiang Wusiyuan Communication Technology Co., Ltd. received support from SPDB for its industrial park construction and equipment procurement, showcasing the bank's commitment to fostering innovation in the robotics sector [4][5] - SPDB's rapid response to the needs of innovative companies like Jiachen Xihai Biotechnology Co., Ltd. demonstrates its ability to provide timely funding, such as a 60 million yuan research loan, to help them navigate the challenges of the biopharmaceutical industry [6][7] Group 3: Strategic Initiatives and Future Outlook - SPDB has positioned technology finance as a primary strategic focus, enhancing its organizational structure to better serve technology enterprises [6][9] - The bank's innovative financing models, such as the "domestic guarantee + overseas loan" approach for mergers and acquisitions, have facilitated significant transactions for companies like Estun [8] - SPDB aims to become a key partner in the technology finance ecosystem, driving high-quality economic development and supporting the modernization of the industrial system in China [9][10]